Health Economics: The Best Books, in Order
Health care breaks the ordinary market model in specific, well-understood ways — the patient does not choose, the buyer does not pay, the seller sets the price after the service, and nobody can shop while unconscious. This path establishes those departures first in plain language, then does the formal apparatus properly through two graduate textbooks, then looks at where American health spending actually goes, then sets the competing policy prescriptions against each other without adjudicating. The final stage is for readers who need the working tools: cost-effectiveness methodology and the historical account of how the profession acquired its market power.
Why this market is different
BeginnerUnderstand moral hazard, adverse selection, third-party payment and supplier-induced demand well enough to see them operating in any health system
▸ Study plan for this stage
Pace: 3-4 weeks. Fuchs is 178pp, Kling 120pp and Reid 304pp — about 600 pages of general-audience prose with no mathematics, so this whole stage moves quickly. Read Fuchs first and slowly despite its length; it is the conceptual foundation for everything after. Kling is a short-form policy essay rather th
- Health care as a choice among competing goods under scarcity — Fuchs's central and still-contested framing
- Moral hazard: insured patients consume more care than they would at true prices
- Adverse selection and why voluntary insurance markets unravel without a mechanism to prevent it
- Third-party payment — the patient does not pay, the payer does not choose, and both incentives distort
- Supplier-induced demand and physician agency: the seller diagnoses the buyer's need
- Premium medicine as the driver of spending growth (Kling's argument) versus waste, fraud or greed
- The four basic financing models — Beveridge, Bismarck, national health insurance, out-of-pocket — from Reid, and which countries use which
- What does Fuchs mean by saying health care is a choice among competing goods, and who disputes that framing?
- Distinguish moral hazard from adverse selection with a concrete example of each in an insurance market you know.
- What is Kling's explanation for American spending growth, and what evidence would refute it?
- Name Reid's four financing models and place five countries into them, including the United States, which uses more than one.
- Why can a patient not shop for care the way they shop for a car — list every distinct reason these three books give.
- Take your own or a family member's most recent medical encounter and identify who chose, who paid and who set the price. This is Fuchs's framework applied in fifteen minutes and it never stops being useful.
- Write out Kling's premium-medicine argument in three sentences, then look up your country's spending growth by category and see whether the composition matches what he predicts.
- For each of Reid's five countries, note what he says the system does badly. He is generally sympathetic, and collecting the criticisms is the corrective to reading him as an advocate.
- Predict, before opening any textbook, which of these concepts you expect to be formalised mathematically in the next stage and how. Checking your prediction is the fastest way to see what a model adds.
Next up: You now have the intuitions in plain language; the textbooks put them into demand curves, utility functions and estimated elasticities, which is what makes them arguable with evidence rather than anecdote.
Fuchs founded the field, and this 1974 book still states its central problem better than anything since: health care is a choice among competing goods under scarcity, and pretending otherwise is where policy goes wrong. Short, and the right first book.
A brief, clear argument that American spending growth is driven by premium medicine — more specialists and more equipment — rather than by waste or greed. Read it second because it makes the core economic mechanism concrete before any textbook formalises it.
Reid takes one shoulder to doctors in five countries and reports what each system does with it. The most painless introduction to the four basic financing models, and it establishes the comparative frame the policy stage needs.
The formal framework
IntermediateWork through the standard models — insurance demand, the RAND experiment, physician agency, hospital behaviour — with the mathematics done properly
▸ Study plan for this stage
Pace: 4-6 months, and this is a different kind of reading from every other stage on this path. Folland, Goodman and Stano is a 648-page undergraduate textbook and Bhattacharya, Hyde and Tu is a 622-page treatment aimed higher — these are not trade books and cannot be read like the previous stage. Expect a
- The demand for health versus the demand for health care, and the Grossman model of health as a capital stock
- Insurance demand under risk aversion, and the welfare loss from moral hazard drawn properly
- The RAND Health Insurance Experiment — design, findings on price elasticity, and what it did and did not settle
- Physician agency models and the empirical literature on supplier-induced demand
- Hospital behaviour under non-profit ownership, and why the objective function is not obvious
- Adverse selection formalised: pooling and separating equilibria, and the death spiral
- Production of health: the flat-of-the-curve argument and the weak marginal return to additional medical care
- Comparative systems treated with data rather than anecdote, which is Bhattacharya's particular strength
- State the Grossman model's central claim and explain why it treats health as an investment rather than a consumption good.
- What did the RAND experiment find about the price elasticity of demand for care, and what did it find about health outcomes? The two answers are not the same and the distinction carries most of the policy debate.
- Draw the welfare-loss triangle from moral hazard and say precisely what is being lost and by whom.
- How does a non-profit hospital's objective function differ from a firm's, and what predictions follow?
- Where does Bhattacharya's empirical treatment revise or complicate something Folland teaches as settled?
- Work the end-of-chapter problems in Folland's insurance and moral hazard chapters rather than reading past them. This is the only stage on the path where doing the problems is the whole point, and skipping them leaves you with vocabulary rather than tools.
- Reproduce the RAND elasticity estimate from the numbers as Folland reports them, and check your arithmetic against the text. Getting the figure yourself is what makes it stick.
- Take one claim from Kling or Reid in the previous stage and find where it is formalised in Folland. Watching a plain-language argument turn into a model is the transition this stage exists for.
- For one of Bhattacharya's empirical chapters, write down the identification strategy of the headline study in two sentences. If you cannot, that is the intermediate-micro and econometrics background the book assumes.
- Note where the two textbooks disagree on emphasis — Folland is more institutional, Bhattacharya more empirical — and decide which you would keep on the shelf.
Next up: With the models in hand, the reporting in the next stage stops being outrage and becomes readable as price formation in a market with the specific defects you can now name.
Folland, Goodman and Stano is the most widely assigned undergraduate text in the field, and the gentlest of the three: it teaches the microeconomics as it goes rather than assuming it. Start the formal stage here.
Bhattacharya, Hyde and Tu, published by Palgrave — the modern graduate treatment, unusually strong on the empirical literature and on comparative systems. Frank Sloan and Chee-Ruey Hsieh's MIT Press textbook, confusingly published under the identical title, is the alternative if you want more on pharmaceutical economics.
Where the money actually goes
IntermediateSee how prices are really set in American health care, and why the list price bears almost no relation to anything
▸ Study plan for this stage
Pace: 5-6 weeks. An American Sickness 419pp, The Price We Pay 278pp and Money-Driven Medicine 480pp — about 1,180 pages of general-audience reporting, which after the textbooks will feel very fast. Read Rosenthal first for the structural map, Makary second for the cases, Mahar third for the history. Note
- Chargemaster pricing and the near-total disconnection between list price, negotiated price and cost
- Out-of-network and surprise billing as a business model rather than an accident
- Device and pharmaceutical markups, and the intermediaries — pharmacy benefit managers, group purchasing organisations — that take a margin
- Price variation for identical procedures within the same city, and the absence of any mechanism that would close it
- Consolidation: hospital systems acquiring practices and the pricing power that follows
- Investor-owned hospitals and the growth of specialty medicine as the historical route to the current market (Mahar's structural account)
- The distinction between reporting on prices and explaining them, which is where this stage needs the previous one
- How is a hospital chargemaster price actually arrived at, and what is it used for?
- Which of the practices Rosenthal describes are rents in the economic sense, and which are ordinary responses to a badly designed payment system?
- Makary advocates price transparency. What does the economics of the previous stage predict transparency will and will not achieve?
- What does Mahar identify as the historical origin of the incentives Rosenthal and Makary describe?
- Which of the three concepts from stage one — moral hazard, third-party payment, supplier-induced demand — best explains American price levels, and which explains price variation?
- Get an actual explanation of benefits or hospital bill and take it apart line by line using Rosenthal's chapters. She organises the book to make this possible and it is the single most useful hour on the path.
- Look up the published price for one common procedure at three hospitals within fifty miles of you. The spread is Makary's central claim, tested locally.
- Take one billing practice Rosenthal describes and diagram the incentives with the models from the textbook stage. Where the model explains it cleanly and where it does not is worth writing down.
- Read Mahar's account of the rise of investor-owned hospitals and mark every claim she supports with data versus with narrative. She is writing history, not econometrics, and the distinction matters for what you carry forward.
Next up: Once you can see how prices are formed, the competing policy prescriptions become legible as different diagnoses of the same facts rather than as tribal positions.
A physician turned journalist working through the bill line by line — chargemasters, out-of-network billing, device markups. The clearest available account of price formation, and it is reporting rather than theory.
A surgeon on the money games: predatory billing, middlemen, and the wide unexplained variation in what the same procedure costs. Makary is an advocate for price transparency and writes as one, which is worth knowing while reading.
The longer historical account of how American medicine became a market — investor-owned hospitals, specialty medicine, and the incentives that followed. Read it third for the structural story behind the two books of reporting above.
The policy arguments, set against each other
IntermediateHold the market-based and the universal-coverage prescriptions simultaneously and see which evidence each side accepts
▸ Study plan for this stage
Pace: 6-7 weeks. Catastrophic Care 377pp, Priceless 392pp and Which Country Has the World's Best Health Care? 464pp. Read the first two together and the third against them. All three are advocacy: Goldhill is a businessman writing after his father died of a hospital-acquired infection and argues from that
- The insurance-is-the-disease argument: comprehensive coverage removes the price signal that would discipline providers
- Health savings accounts, catastrophic-only coverage and deregulated supply as the market prescription
- The counterargument from concentration of spending — a small share of patients account for most costs, and they exceed any plausible deductible
- Universal coverage designs compared on the same criteria across eleven systems (Emanuel's framework)
- Which evidence each side accepts: the RAND findings are used by both, differently
- Administrative cost, provider prices and utilisation as three separate explanations for cross-country spending differences
- What each author concedes — Emanuel names what his preferred systems do badly, which is the reason he is placed here
- State Goldhill's argument in its strongest form, then state the strongest objection to it from the spending-concentration data.
- What specifically does Goodman propose, and which of his proposals depends on assumptions the textbook stage would question?
- On Emanuel's criteria, which systems perform best and worst, and how sensitive is the ranking to the choice of criteria?
- Both sides cite RAND. What does each side take from it, and is either reading unfair?
- Where do all three authors actually agree? The overlap is larger than the rhetoric suggests and it is worth naming.
- Build a two-column table of Goldhill's and Emanuel's claims on the same five questions — cost control, access, quality, innovation, administrative burden — in their own terms. Doing it fairly is harder than it sounds and is the exercise.
- Take Goodman's health savings account proposal and work through what happens to a patient with a chronic condition costing well above the deductible every year. This is the standard objection and the point is to see whether the book answers it.
- Find the passages where Emanuel criticises a system he favours, and where Goldhill concedes a limit to markets. Both exist; locating them is how you tell advocacy from propaganda.
- Pick one country from Emanuel and check his account against Reid's from stage one. Ten years apart and two purposes; the differences show how much of comparative health policy is framing.
Next up: Arguments about which system is better eventually turn into arguments about whether a specific intervention is worth funding, which is a technical question with an established method and a long institutional history.
The argument that comprehensive insurance is itself the disease: patients who never see a price cannot discipline a market. Goldhill is a businessman writing after his father's hospital death, and it is the most persuasive statement of this position.
The full free-market prescription — health savings accounts, deregulated provision, price competition. Goodman is a partisan and this is an advocacy book; read it directly after Goldhill as the policy version of the same instinct.
Eleven systems compared on the same criteria by an architect of the Affordable Care Act. The counterweight to the previous two, and useful because Emanuel is willing to name what the systems he prefers do badly.
The working tools
IntermediatePerform and read economic evaluations, and understand the institutional history that produced the current market
▸ Study plan for this stage
Pace: 3-4 months. Drummond and colleagues is 464pp and is a working reference and methods text rather than a book you read through — expect to work it chapter by chapter with a real evaluation in front of you, and to return to it for years. Starr's The Social Transformation of American Medicine is 514pp o
- Cost-effectiveness, cost-utility and cost-benefit analysis, and what distinguishes them
- The QALY: how it is constructed, how utilities are elicited, and the standard objections to it
- Discounting future costs and health effects, and why the discount rate is contested rather than technical
- Incremental cost-effectiveness ratios, cost-effectiveness planes and acceptability curves
- Sensitivity analysis and decision-analytic modelling as the standard defence against parameter uncertainty
- Perspective — payer, health system, societal — and how much the answer moves when you change it
- Professional sovereignty: how American physicians won cultural authority and market power, and then lost control to corporations and insurers (Starr's argument)
- Why the market has the institutional shape the models are trying to describe
- Construct a QALY for a hypothetical intervention and state every judgement you had to make. There will be more than you expect.
- Why does the discount rate matter so much for preventive interventions specifically?
- What changes about an evaluation when the perspective shifts from payer to societal, and who bears the costs that appear or vanish?
- According to Starr, how did the medical profession acquire its authority, and which of those mechanisms still operate?
- Where does Starr's institutional history explain something the economic models can only assume — pick a specific model from the textbook stage and answer it.
- Find a published cost-effectiveness analysis of a technology you care about and appraise it against Drummond's checklist, item by item. This is the exact task the book exists for and the checklist is designed to be used this way.
- Build a simple decision tree for a two-arm comparison using Drummond's worked structure, and run a one-way sensitivity analysis on the parameter you are least sure of. Seeing the result flip is the lesson.
- Recompute a published incremental cost-effectiveness ratio from the study's own reported costs and effects, and check it against the stated figure. Doing this once teaches you where the numbers actually come from.
- Read Starr's account of how hospitals became the centre of medicine, then return to the hospital-behaviour chapter in Folland. The model's assumptions stop looking arbitrary once you know the history that produced them.
Next up: This is the end of the path: from here the reading is journal literature — Journal of Health Economics, Health Affairs — and the specific policy or evaluation problem in front of you.
Drummond and colleagues is the standard reference for cost-effectiveness and cost-utility analysis — QALYs, discounting, sensitivity analysis. If you will ever have to appraise a technology, this is the book you actually use.
Starr's Pulitzer-winning history of how the medical profession achieved cultural authority and economic power, and then lost control to corporations and insurers. Not economics, and the best closing book here: it explains why the market has the shape the models are trying to describe.
Discussion
Keep reading
Paths that share books, cover the same subject, or open a related topic.
